BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting

Independent Study Indicates 20-50% Improvement in Post-Preservation Functional Recovery of Peripheral Blood Stem Cells for Cancer Therapy

BOTHELL, Wash., June 25, 2007 /PRNewswire-FirstCall/ -- BioLife Solutions Inc. , a leading developer and marketer of proprietary hypothermic storage and cryopreservation media products for cells, tissues, and organs, today presented data from an independent study of its CryoStor family of cryopreservation media at the annual meeting of the International Society for Cellular Therapy in Sydney, Australia.

The presentation by BioLife scientists summarized the results of a recent study conducted by researchers at the Fred Hutchinson Cancer Research Center (FHCRC) and the University of Washington. BioLife's CryoStor preservation media was compared with a DMSO/HSA media formulation, currently considered the "gold standard" for cryopreservation of peripheral blood stem cells. Peripheral blood stem cells are the most common source of stem cells for transplantation to treat various blood disorders such as leukemia.

Highlighted metrics evaluated in the study included Colony Forming Units (CFU), a key indicator of the functional ability of cells to divide and replicate following cryopreservation, and total CD34+ cell recovery, a key marker of a subpopulation of undifferentiated progenitor cells that are of critical interest to researchers focused on hematopoietic cell therapies. The results of the study showed that BioLife's CryoStor technology platform produced a 20-50% relative improvement across these key parameters in comparison to the 10% DMSO standard preservation media utilized at FHCRC.

Shelly Heimfeld, director of the cellular therapy laboratory at the Fred Hutchinson Cancer Research Center, commented: "We were impressed by how much better the CryoStor patented media formulations improved the post-preservation recovery of CD34+ and colony-forming cells. We will continue our evaluations and validation of BioLife's products with the hope to incorporate CryoStor into our clinical applications."

BioLife Chief Executive Mike Rice remarked: "We're very pleased that world-class institutions like the Fred Hutchinson Cancer Research Center and the University of Washington have confirmed the value of BioLife's intellectual property and CryoStor products which provide unique benefits to clinicians in their fight against cancer and other diseases. The data from this independent comparative evaluation of CryoStor is consistent with results of our internal research. Awareness of our enabling technology is growing as clinical researchers and care givers realize how our proprietary products can enhance their biologic-based therapies and services."

According to an August 2006 research report published by Jain PharmaBiotech, the total value of cell-based markets was $27 billion in 2005 and is expected to grow to $96 billion in 2015, as more than 300 companies are engaged in developing cell-based alternatives to medical devices and drugs to treat and possibly cure numerous acute and chronic diseases. Additionally, PA Consulting Group, a global consulting firm with expertise in life sciences and healthcare, estimates the worldwide market for media to preserve cells,

tissues, and organs for research and clinical applications will grow to from $200 million in 2007 to more than $300 million by 2011.

About BioLife Solutions

BioLife Solutions develops, manufactures and markets patented hypothermic storage and cryopreservation solutions for cells, tissues, and organs. The Company's proprietary HypoThermosol(R) and CryoStor(TM) platform of solutions are marketed to academic and commercial organizations involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife's products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced, delayed-onset cell damage and death. BioLife's enabling technology provides academic and clinical researchers significant improvements in post-thaw cell, tissue, and organ viability and function. For more information please visit http://www.biolifesolutions.com.

This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

    Media Relations:                  Investor Relations:

    Len Hall                          Matt Clawson

    Allen & Caron Inc.                Allen & Caron Inc.

    (949) 474-4300                    (949) 474-4300

                    

len@allencaron.com matt@allencaron.com

CONTACT: Media Relations, Len Hall, , or InvestorRelations, Matt Clawson, , both of Allen & Caron Inc.,+1-949-474-4300, for BioLife Solutions Inc. len@allencaron.com matt@allencaron.com

Web site: http://www.biolifesolutions.com/

Ticker Symbol: (NASDAQ-OTCBB:BLFS)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: June 2007

View comments

Hide
(web3)